Login / Signup

What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment.

Kerrie-Anne HoMustafa AcarAndrea PuigGabor HutasSimon J Fifer
Published in: Clinical rheumatology (2019)
For most patients with IA, clinical efficacy, stopping disease progression and risks of mild-to-moderate side effects are important treatment attributes. Patients with prior biologic DMARD experience had greater preference for injection treatments. For a subset of patients, patient support programmes and the frequency of administration were important. Clinicians should be mindful of preferences when prescribing treatment to patients with IA.Key Points• Most patients consider clinical efficacy, stopping disease progression and the risk of mild-to-moderate side effects as important treatment attributes• Patients with prior biologic DMARD experience have greater preference for injection treatments.• For a subset of patients, patient support programmes, and the frequency of administration were important.• Clinicians should be mindful of preferences when prescribing treatment to patients with IA.
Keyphrases
  • end stage renal disease
  • rheumatoid arthritis
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • emergency department
  • peritoneal dialysis
  • palliative care
  • decision making
  • adverse drug
  • smoking cessation